Fiche personne
Directeur général de l'Institut Jean Godinot
Territoire
Champagne-Ardenne
Statut
Hospitalo-Universitaire
Équipes/plateformes
Recherche
Expertises :
- Clinique:Oncologie Médicale
Publications
Base of tongue volume and dose as predictors of late dysphagia after definitive or adjuvant radiotherapy for oral cavity squamous cell carcinoma.
Azria J, Beddok A, Brenet E, Antoni D, Auzeau L, Assouly N, Fontaine M, Guendouzen S, Merol JC, Merrouche Y, Guilbert P, Da Silva Ribeiro Mota A
Phys Imaging Radiat Oncol. 2026 07;40:101038
Breast Cancer Diagnosis and HER2+ Versus Triple Negative Discrimination by Infrared Spectral Histopathology.
El Tahech H, Lerévérend C, Kane S, Fichel C, Hassani J, Trévoux S, Untereiner V, Lehmann-Che J, Maquin C, Corsois L, Merrouche Y, Vuiblet V, Bolko L, Salmon JH, Piot O, Potteaux S, Gobinet C
Anal Chem. 2026 06 9;:
Safety of concurrent T-DM1 and radiation therapy in HER2-positive breast cancer with residual disease after neoadjuvant chemotherapy.
Beddok A, Girres L, Torielli P, Vigneau E, Ettalhaoui L, Hotton J, Jouannaud C, Mazza C, Lemoine A, Parent D, Roque A, Soibinet P, Vignot S, Merrouche Y, Guilbert P
Int J Radiat Biol. 2026 06 4;:1-8
Improving CTV delineation after preoperative systemic therapy in breast cancer using deformable PET/CT registration.
Kemmeugne J, Gallay L, Morland D, Hotton J, Jouannaud C, Merrouche Y, Papathanassiou D, Reyal F, Ndéo Sene M, Torielli P, Vignot S, Guilbert P, Beddok A
Breast. 2026 03 23;87:104752
In Vitro Model of Cytokine-Induced Inflammatory 3T3-L1 Adipocytes Mimicking Obesity.
Cartier L, Fournet R, De Boni M, Kotaich N, Laassili C, Merrouche Y, Potteaux S
Bio Protoc. 2026 02 20;16(4):e5609
Currents status of radiotracers for breast cancer imaging in PET.
Jean C, Roux S, Aziz A, Mocquery-Corre M, Bazzi R, Merrouche Y, Dedieu S, Etique N, Papathanassiou D, Devy J
Transl Oncol. 2025 02 6;53:102304
Improving Medical Education in Oncology: Enhancing Students' Understanding of Cancer Treatments Through Multidisciplinary Clinical Rotations.
Beddok A, Bouazzi L, Barbe C, Martin P, Gratiaux J, Guilbert P, Job L, Lemoine A, Morland D, Papathanassiou D, Perin S, Merrouche Y, Nifosi G, Soibinet P, Vignot S, Hotton J
J Cancer Educ. 2025 01 27;:
Enhanced expression of galectin-9 in triple negative breast cancer cells following radiotherapy: Implications for targeted therapy.
Lerévérend C, Kotaich N, Cartier L, De Boni M, Lahire S, Fichel C, Thiebault C, Brabencova E, Maquin C, Barbosa E, Corsois L, Hotton J, Guendouzen S, Guilbert P, Lepagnol-Bestel AM, Cahen-Doidy L, Lehmann-Che J, Devy J, Bensussan A, Le Jan S, Pommier A, Merrouche Y, Le Naour R, Vignot S, Potteaux S
Int J Cancer. 2024 07 30;:
Long term survival in adult osteosarcoma patients treated with a two-drug regimen: Final results of the OSAD93 phase II study of the FSG-GETO.
Blay JY, Penel N, Toulmonde M, Valentin T, Chaigneau L, Rios M, Saada-Bouzid E, Firmin N, Bertucci F, Marec-Berard P, Ray-Coquard I, Lervat C, Rolland F, Thyss A, Conroy T, Brahmi M, Dufresne A, Merrouche Y, Brunat-Mentigny M, Biron P, Bompas E, Perol D,
Eur J Cancer. 2024 07 15;208:114228
Identification of CD160-TM as a tumor target on triple negative breast cancers: possible therapeutic applications.
Scheffges C, Devy J, Giustiniani J, Francois S, Cartier L, Merrouche Y, Foussat A, Potteaux S, Bensussan A, Marie-Cardine A
Breast Cancer Res. 2024 02 15;26(1):28
Mild dyslipidemia accelerates tumorigenesis through expansion of Ly6C monocytes and differentiation to pro-angiogenic myeloid cells.
Tran T, Lavillegrand JR, Lereverend C, Esposito B, Cartier L, Montabord M, Tran-Rajau J, Diedisheim M, Gruel N, Ouguerram K, Paolini L, Lenoir O, Pinteaux E, Brabencova E, Tanchot C, Urquia P, Lehmann-Che J, Le Naour R, Merrouche Y, Stockmann C, Mallat Z, Tedgui A, Ait-Oufella H, Tartour E, Potteaux S
Nat Commun. 2022 09 14;13(1):5399
One-year COVID-19 outcomes on the oncology care patient pathway: Results of a French descriptive, cross-sectional comprehensive study (ONCOCARE-COV).
Laurent L, Brugel M, Carlier C, Clere F, Bertrand A, Botsen D, Boulagnon-Rombi C, Dalstein V, Debreuve-Theresette A, Deguelte S, Garbar C, Mahmoudi R, Marechal A, Morland D, Rey JB, Schvartz C, Vallet C, Merrouche Y, Slimano F, Bouché O
Cancer Med. 2022 05 20;:
Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France.
Blay JY, Boucher S, Le Vu B, Cropet C, Chabaud S, Perol D, Barranger E, Campone M, Conroy T, Coutant C, De Crevoisier R, Debreuve-Theresette A, Delord JP, Fumoleau P, Gentil J, Gomez F, Guerin O, Jaffré A, Lartigau E, Lemoine C, Mahe MA, Mahon FX, Mathieu-Daude H, Merrouche Y, Penault-Llorca F, Pivot X, Soria JC, Thomas G, Vera P, Vermeulin T, Viens P, Ychou M, Beaupere S
ESMO Open. 2021 Apr 17;6(3):100134
Dramatic changes in oncology care pathways during the COVID-19 pandemic: The French ONCOCARE-COV study.
Brugel M, Carlier C, Essner C, Debreuve-Theresette A, Beck MF, Merrouche Y, Bouché O
Oncologist. 2020 Oct 28;:
The Interleukin-17 Family of Cytokines in Breast Cancer.
Fabre JAS, Giustinniani J, Garbar C, Merrouche Y, Antonicelli F, Bensussan A
Int J Mol Sci. 2018 Dec 4;19(12):
[HBV infection: Screening and treatment for oncology patients].
Jaillais A, Herber-Mayne A, D'Alteroche L, Landau A, Merrouche Y, Vignot S
Bull Cancer. 2018 Feb;105(2):162-170
Triple-negative and HER2-overexpressing breast cancer cell sialylation impacts tumor microenvironment T-lymphocyte subset recruitment: a possible mechanism of tumor escape.
Garbar C, Mascaux C, Merrouche Y, Bensussan A
Cancer Manag Res. 2018 ;10:1051-1059
[Mobile applications for French medical students: Work in progress].
Vignot S, Servagi-Vernat S, Brouard B, Merrouche Y
Presse Med. 2017 Sep;:
Chemotherapy treatment induces an increase of autophagy in the luminal breast cancer cell MCF7, but not in the triple-negative MDA-MB231.
Garbar C, Mascaux C, Giustiniani J, Merrouche Y, Bensussan A
Sci Rep. 2017 Aug;7(1):7201
[Obesity and cancer].
Salaün H, Thariat J, Vignot M, Merrouche Y, Vignot S
Bull Cancer. 2017 Jan;104(1):30-41
IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells.
Merrouche Y, Fabre J, Cure H, Garbar C, Fuselier C, Bastid J, Antonicelli F, Al-Daccak R, Bensussan A, Giustiniani J
Oncotarget. 2016 Aug;7(33):53350-53361
Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type.
Fabre J, Giustiniani J, Garbar C, Antonicelli F, Merrouche Y, Bensussan A, Bagot M, Al-Dacak R
Int J Mol Sci. 2016 Aug;17(9):
Identification of CD245 as myosin 18A, a receptor for surfactant A: A novel pathway for activating human NK lymphocytes.
De Masson A, Giustiniani J, Marie-Cardine A, Bouaziz JD, Dulphy N, Gossot D, Validire P, Tazi A, Garbar C, Bagot M, Merrouche Y, Bensussan A
Oncoimmunology. 2016 May;5(5):e1127493
Translating Clinical Evidence-Based Medicine into the Real World: Single-Center Experience with Cabazitaxel in Metastatic Prostate Cancer Patients.
Moriceau G, Guillot A, Pacaut C, Méry B, Falk AT, Trone JC, Collard O, De Laroche G, Fournel P, Merrouche Y, Magné N
Chemotherapy. 2016 ;61(3):127-33
Uterine and ovary carcinosarcomas: outcome, prognosis factors, and adjuvant therapy.
Pacaut C, Bourmaud A, Rivoirard R, Moriceau G, Guy JB, Collard O, Bosacki C, Jacquin JP, Levy A, Chauleur C, Magné N, Merrouche Y
Am. J. Clin. Oncol.. 2015 Jun;38(3):272-7
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.
,Thaler J, Greil R, Gaenzer J, Eisterer W, Tschmelitsch J, Samonigg H, Zabernigg A, Schmid F, Steger G, Steinacher R, Andel J, Lang A, Függer R, Hofbauer F, Woell E, Geissler D, Lenauer A, Prager M, Van Laethem JL, Van Cutsem E, D'Haens G, Demolin G, Kerger J, Deboever G, Ghillebert G, Polus M, Van Cutsem E, RezaieKalantari H, Delaunoit T, Goeminne JC, Peeters M, Vergauwe P, Houbiers G, Humblet Y, Janssens J, Schrijvers D, Vanderstraeten E, Van Laethem JL, Vermorken J, Van Daele D, Ferrante M, Forget F, Hendlisz A, Yilmaz M, Nielsen SE, Vestermark L, Larsen J, Ychou M, Zawadi A, Zawadi MA, Bouche O, Mineur L, Bennouna-Louridi J, Dourthe LM, Ychou M, Boucher E, Taieb J, Pezet D, Desseigne F, Ducreux M, Texereau P, Miglianico L, Rougier P, Fratte S, Levache CB, Merrouche Y, Ellis S, Locher C, Ramee JF, Garnier C, Viret F, Chauffert B, Cojean-Zelek I, Michel P, Lecaille C, Borel C, Seitz JF, Smith D, Lombard-Bohas C, Andre T, Gornet JM, Fein F, Coulon-Sfairi MA, Kaminsky MC, Lagasse JP, Luet D, Etienne PL, Gasmi M, Vanoli A, Nguyen S, Aparicio T, Perrier H, Stremsdoerfer N, Laplaige P, Arsene D, Auby D, Bedenne L, Coriat R, Denis B, Geoffroy P, Piot G, Becouarn Y, Bordes G, Deplanque G, Dupuis O, Fruge F, Guimbaud R, Lecomte T, Lledo G, Sobhani I, Asnacios A, Azzedine A, Desauw C, Galais MP, Gargot D, Lam YH, Abakar-Mahamat A, Berdah JF, Catteau S, Clavero-Fabri MC, Codoul JF, Legoux JL, Goldfain D, Guichard P, Verge DP, Provencal J, Vedrenne B, Brezault-Bonnet C, Cleau D, Desir JP, Fallik D, Garcia B, Gaspard MH, Genet D, Hartwig J, Krummel Y, MatysiakBudnik T, Palascak-Juif V, Randrianarivelo H, Rinaldi Y, Aleba A, Darut-Jouve A, de Gramont A, Hamon H, Wendehenne F, Matzdorff A, Stahl MK, Schepp W, Burk M, Mueller L, Folprecht G, Geissler M, Mantovani-Loeffler L, Hoehler T, Asperger W, Kroening H, von Weikersthal LF, Fuxius S, Groschek M, Meiler J, Trarbach T, Rauh J, Ziegenhagen N, Kretzschmar A, Graeven U, Nusch A, von Wichert G, Hofheinz RD, Kleber G, Schmidt KH, Vehling-Kaiser U, Baum C, Schuette J, Haag GM, Holtkamp W, Potenberg J, Reiber T, Schliesser G, Schmoll HJ, Schneider-Kappus W, Abenhardt W, Denzlinger C, Henning J, Marxsen B, GuenterDerigs H, Lambertz H, Becker-Boost I, Caca K, Constantin C, Decker T, Eschenburg H, Gabius S, Hebart H, Hoffmeister A, Horst HA, Kremers S, Leithaeuser M, Mueller S, Wagner S, Daum S, Schlegel F, Stauch M, Heinemann V, Labianca R, Colucci G, Amadori D, Mini E, Falcone A, Boni C, Maiello E, Latini L, Zaniboni A, Amadori D, Aprile G, Barni S, Mattioli R, Martoni A, Passalacqua R, Nicolini M, Pasquini E, Rabbi C, Aitini E, Ravaioli A, Barone C, Biasco G, Tamberi S, Gambi A, Verusio C, Marzola M, Lelli G, Boni C, Cascinu S, Bidoli P, Vaghi M, Cruciani G, Di Costanzo F, Sobrero A, Mini E, Petrioli R, Aglietta M, Alabiso O, Capuzzo F, Falcone A, Corsi DC, Labianca R, Salvagni S, Chiara S, Ferraù F, Giuliani F, Lonardi S, Gebbia N, Mantovani G, Sanches E, Sanches E, Mellidez JC, Santos P, Freire J, Sarmento C, Costa L, Pinto AM, Barroso S, Santo JE, Guedes F, Monteiro A, Sa A, Furtado I, Tabernero J, Salazar R, Aguilar EA, Herrero FR, Tabernero J, Valera JS, ValladaresAyerbes M, FeliuBatlle J, Gil S, Garcia-Giron C, Vivanco GL, Salvia AS, Orduña VA, Garcia RV, Gallego J, Sureda BM, Remon J, Safont Aguilera MJ, CireraNogueras L, Merino B, Castro CG, de Prado PM, PijaumePericay C, ConstenlaFigueiras M, Jordan I, GomeReina MJ, Garcia AL, Garcia-Ramos AA, Cervantes A, Martos CF, MarcuelloGaspar E, Montero IC, Emperador PE, Carbonero AL, Castillo MG, Garcia TG, Lopez JG, Flores EG, GuillotMorales M, LlanosMuñoz M, Martín AL, Maurel J, Camara JC, Garcia RD, Salgado M, HernandezBusquier I, Ruiz TC, LacastaMuñoa A, Aliguer M, Ortiz de Taranco AV, Ureña MM, Gaspa FL, Ponce JJ, Roig CB, Jimenez PV, GalanBrotons A, AlbiolRodriguez S, Martinez JA, Ruiz LC, CentellesRuiz M, Bridgewater J, Glynne-Jones R, Tahir S, Hickish T, Cassidy J, Samuel L
Ann. Oncol.. 2015 Apr;26(4):822-825
Radiotherapy for head and neck cancer in nonagenarian patients: a possible cornerstone?
Rivoirard R, Moncharmont C, Assouline A, Auberdiac P, Mery B, Falk AT, Annède P, Trone JC, Guy JB, Vial N, Fournel P, Merrouche Y, Chargari C, Magné N
Eur Arch Otorhinolaryngol. 2015 Mar;272(3):719-25
IL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells.
Mombelli S, Cochaud S, Merrouche Y, Garbar C, Antonicelli F, Laprevotte E, Alberici G, Bonnefoy N, Eliaou JF, Bastid J, Bensussan A, Giustiniani J
Sci Rep. 2015 Jul 8;5:11874
[Assessment of screening in women cancers and in 75 years older in Loire department].
Swalduz A, Guibert C, Trone JC, Guichard JB, Rivoirard R, Pacaut C, Méry B, Guy JB, Eddekkaoui H, Fournel P, de Laroche G, Merrouche Y, Magné N
Bull Cancer. 2014 Sep;101(9):808-12
Portrait, treatment choices and management of breast cancer in nonagenarians: an ongoing challenge.
Méry B, Assouline A, Rivoirard R, Bosacki C, Auberdiac P, Falk AT, Trone JC, Guy JB, Jacquin JP, Merrouche Y, Chargari C, Magné N
Breast. 2014 Jun;23(3):221-5
Feasibility of radiation therapy in patients 90years of age and older: a French multicentre analysis.
Chargari C, Moriceau G, Auberdiac P, Guy JB, Assouline A, Tinquaut F, Falk AT, Eddekkaoui H, Bourmaud A, Coscas Y, Annede P, Rivoirard R, Mery B, Trone JC, Otmezguine Y, Pacaut C, Bauduceau O, Vedrine L, Merrouche Y, Magne N
Eur. J. Cancer. 2014 May;50(8):1490-7
Is oral chemotherapy prescription safe for patients? A cross-sectional survey.
Bourmaud A, Pacaut C, Melis A, Tinquaut F, Magné N, Merrouche Y, Chauvin F
Ann. Oncol.. 2014 Feb;25(2):500-4
General management of nonagenarian patients: a review of the literature.
Rivoirard R, Chargari C, Trone JC, Falk AT, Guy JB, Eddekaoui H, Lahmar R, Pacaut C, Mery B, Assouline A, Auberdiac P, Moriceau G, Gonthier R, Guillot A, Merrouche Y, Magné N
Swiss Med Wkly. 2014 ;144:w14059
[The announcement of the diagnosis of cancer: point of view of the general practitioner].
Ferraton-Rollin M, Magné N, Gonthier R, Merrouche Y, Bois C
Bull Cancer. 2013 Oct;100(10):955-62
Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer-Study BES 06.
Villanueva C, Romieu G, Salvat J, Chaigneau L, Merrouche Y, N'guyen T, Vuillemin AT, Demarchi M, Dobi E, Pivot X
Target Oncol. 2013 Jun;8(2):137-43
Reappraisal of the role of bevacizumab in the therapeutic strategy in advanced renal cell carcinoma.
Guillot A, Levy A, Pacaut C, Collard O, Massard C, Merrouche Y, Magné N
Clin Genitourin Cancer. 2012 Sep;10(3):147-52
Recommendations for a lifestyle which could prevent breast cancer and its relapse: physical activity and dietetic aspects.
Magné N, Melis A, Chargari C, Castadot P, Guichard JB, Barani D, Nourissat A, Largillier R, Jacquin JP, Chauvin F, Merrouche Y
Crit. Rev. Oncol. Hematol.. 2011 Dec;80(3):450-9
Sarcoma of vulva, vagina and ovary.
Magné N, Pacaut C, Auberdiac P, Jacquin JP, Chargari C, Chauleur C, Haie Meder C, Merrouche Y
Best Pract Res Clin Obstet Gynaecol. 2011 Dec;25(6):797-801
Ultraviolet recall dermatitis reaction with sorafenib.
Magné N, Chargari C, Auberdiac P, Moncharmont C, Merrouche Y, Spano JP
Invest New Drugs. 2011 Oct;29(5):1111-3
[Assessment of daily physical activity of breast cancer patients and comparison with two control populations].
Guichard JB, Garet M, Auberdiac P, Nourissat A, Roche F, Mélis A, Barthélémy JC, Chauvin F, Da Costa A, Chargari C, Merrouche Y, Jacquin JP, Collard O, Magné N
Bull Cancer. 2011 Jul;98(7):733-40
Reappraisal of the role of hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of ovarian cancer: a single institutional experience.
Melis A, Abboud K, Bourmaud A, Pacaut C, Bageacu S, Jacquin JP, Porcheron J, Merrouche Y, Magné N
Bull Cancer. 2011 Jun;:
[Carcinoma of the anal canal: state of art, issues in geriatric oncology and molecular targeted therapies].
Hau Desbat NH, Auberdiac P, Chargari C, Merrouche Y, Deutsch E, Schmitt T, de Laroche G, Magné N
Bull Cancer. 2011 Feb;98(2):146-53
[Cisplatin or carboplatin, that is the question].
Moncharmont C, Auberdiac P, Mélis A, Afqir S, Pacaut C, Chargari C, Merrouche Y, Magné N
Bull Cancer. 2011 Feb;98(2):164-75
Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study.
Freyer G, Duret A, Milano G, Chatelut E, Rebischung C, Delord JP, Merrouche Y, Lledo G, Etienne MC, Falandry C
Anticancer Res.. 2011 Jan;31(1):359-66
Improvement of malignant serous effusions diagnosis by quantitative analysis of molecular claudin 4 expression.
Mohamed F, Vincent N, Cottier M, Peoc'h M, Merrouche Y, Patouillard B, Paul S, Genin C
Biomarkers. 2010 Jun;15(4):315-24
Relationship between nutritional status and quality of life in patients with cancer.
Nourissat A, Vasson MP, Merrouche Y, Bouteloup C, Goutte M, Mille D, Jacquin JP, Collard O, Michaud P, Chauvin F
Eur. J. Cancer. 2008 Jun;44(9):1238-42
Estimation of the risk for nutritional state degradation in patients with cancer: development of a screening tool based on results from a cross-sectional survey.
Nourissat A, Mille D, Delaroche G, Jacquin JP, Vergnon JM, Fournel P, Seffert P, Porcheron J, Michaud P, Merrouche Y, Chauvin F
Ann. Oncol.. 2007 Nov;18(11):1882-6
Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
Massard C, Voigt JJ, Laplanche A, Culine S, Lortholary A, Bugat R, Theodore C, Priou F, Kaminsky MC, Lesimple T, Pivot X, Coudert B, Douillard JY, Merrouche Y, Fizazi K
Br J Cancer. 2007 Oct 8;97(7):857-61
[Recommendations for clinical practice: management with first-line palliative chemotherapy for patients with metastatic colorectal cancer].
Conroy T, Adeni A, Bouché O, Merrouche Y, Mitry E, Gory-Delabaere G, ,,,,,,,,,
Bull Cancer. 2006 Feb;93(2):197-200
[Clinical practice guideline: 2003 update of Standards, Options et Recommendations for first line palliative chemotherapy in patients with metastatic colorectal cancer (summary report)].
Conroy T, Gory-Delabaere G, Adenis A, Bosquet L, Bouché O, Louvet C, Mitry E, Bécouarn Y, Bosset JF, Ducreux M, Etienne PL, Merrouche Y, Monges G, Rougier P, ,,,,,,,
Bull Cancer. 2004 Oct;91(10):759-68
[Clinical practice guidelines: 2004 Standards, Options and Recommendations for the management of patient with adenocarcinoma of the stomach--radiotherapy].
Ychou M, Gory-Delabaere G, Blanc P, Bosquet L, Duffour J, Giovannini M, Guillemin F, Lemanski C, Marchal F, Masson B, Merrouche Y, Monges G, Adenis A, Bosset JF, Bouché O, Conroy T, Pezet D, Triboulet JP, ,,
Cancer Radiother. 2004 Oct;8(5):322-35
Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01).
Culine S, Lortholary A, Voigt JJ, Bugat R, Théodore C, Priou F, Kaminsky MC, Lesimple T, Pivot X, Coudert B, Douillard JY, Merrouche Y, Allouache J, Goupil A, Négrier S, Viala J, Petrow P, Bouzy J, Laplanche A, Fizazi K,
J. Clin. Oncol.. 2003 Sep;21(18):3479-82
